• Media Centre
  • Investor relations
  • Client area
  • Client area
  • Stewardship policy
  • Annual reports service

Form of Proxy

TAYSHA GENE THERAPIES, INC.

Notes

No. Proposition For Against Abstain
1

DIRECTOR Phillip B Donenberg CPA

2

DIRECTOR Sukumar Nagendran, MD

3

To ratify the selection by the Audit Committee of the Board of Directors of Deloitte & Touche LLP as the independent registered public accounting firm of the Company for the year ending December 31, 2025.

4

To approve a proposed amendment to the Companys Amended and Restated Certificate of Incorporation, as amended to date, to increase the number of authorized shares of common stock from 400,000,000 to 700,000,000 shares.